Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
Boehringer Ingelheim
Boehringer Ingelheim
National Cancer Institute (NCI)
Bristol-Myers Squibb
Bristol-Myers Squibb
Bristol-Myers Squibb
Merck Sharp & Dohme LLC
PMV Pharmaceuticals, Inc
Mayo Clinic
Eli Lilly and Company
Pfizer
Hoffmann-La Roche
Canadian Cancer Trials Group
Roswell Park Cancer Institute
Merck Sharp & Dohme LLC
Revolution Medicines, Inc.
Verastem, Inc.
Alliance for Clinical Trials in Oncology
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Amgen
Pfizer
Tizona Therapeutics, Inc
Merck Sharp & Dohme LLC
Essen Biotech
Emory University
Emory University
Eli Lilly and Company
Gazi University
VA Office of Research and Development
Pfizer
Eli Lilly and Company
VM Oncology, LLC
University of Washington
Tango Therapeutics, Inc.
Krystal Biotech, Inc.
The Christ Hospital
Latin American Cooperative Oncology Group
Institute of Cancer Research, United Kingdom
Mirati Therapeutics Inc.
Chinese University of Hong Kong
Fundación GECP
Teclison Ltd.
Vanderbilt-Ingram Cancer Center
Essen Biotech
Second Affiliated Hospital of Guangzhou Medical University
Hunan Province Tumor Hospital
Second Affiliated Hospital of Guangzhou Medical University
Rutgers, The State University of New Jersey
Lithuanian University of Health Sciences